Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia

Summary

Splenectomized thalassemia major subjects were provided with PCV pneumococcal vaccine (Prevenar 13®) at the start of the trial, following which they were randomly assigned to 2 groups (zinc and placebo group). After 8 weeks, the subjects received PPV pneumococcal vaccine (Pneumovax®). Zinc syrup was provided to the zinc group at a dose of 1.5 mg/kg/day (maximum of 50 mg/day). Pneumococcal IgG examinations were conducted at the start of the trial and after 12 weeks.

Timeline

Start

2013-09-01

Primary completion

2014-02-01

Completion

2014-02-01

Drugs

Indications